Authors: P. Basto, F. Alexis, E. Levy-Nissenbaum, R. Langer and O. Farokzhad
Affilation: Massachusetts Institute of Technology, United States
Pages: 366 - 369
Keywords: docetaxel, prostate cancer, targeted delivery, poly (D, L-lactic-co-glycolic acid) (PLGA)
Using prostate cancer as a model, we report the drug release of pacitaxel and doxorubicin from aptamer-poly (D,L lactic co glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles used to target prostate-specific membrane antigen (PSMA), a well characterized antigen that is expressed on the surface of prostate cancer cells. Doxorubicin functions as an inhibitor of topoisomoerase II progression to halt replication. Pacitaxel stops the formation of mitotic spindles which interrupts cell division. In our study, the doxorubicin non-covalently intercalated in the aptamer on the surface of the nanoparticles and the pacitaxel is encapsulated within the bulk polymer unit for a powerful delivery method of both drugs at different release rates acting synergistically. In vitro toxicity assays have shown the targeting efficiency of these nanoparticles and the synergistic effect of the two drugs are higher than a single drug delivery system. These targeted drug delivery nanoparticles could be used as a powerful therapeutic tool, in comparison to the single drug approach, to combat cancer cells displaying drug resistance.
Nanotech Conference Proceedings are now published in the TechConnect Briefs